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Summary: Some aspects of the pathogenesis of cardiac disease are reviewed in the light of current knowledge
of the physiological and biochemical actions of magnesium (Mg2"1") on heart function. Several authors have
reported a reduction of the human myocardial Mg2+ content in areas with (Mg2+ poor) soft water, without a
significant alteration of Mg24" in serum or skeletal muscle. In human during myocardial infarction, there is a
reduction· of Mg24" content even in noninfarcted areas of the myocardium, followed by a transient reduction of
serum Mg2"1" concentration. These effects are explained by the action of catecholamines on the myocardial
cells, resulting in a loss of Mg2"1" accompanied by a catecholamine-induced uf inary Mg24" loss and/or increased
lipolysis which binds Mg24" äs Mg24" soaps in the adipocytes. As a consequence serum Mg2"1" may be decreased.
A reduced serum Mg2"1" concentration may enhance the actiori of catecholamines on the heart muscle äs well
äs the action of vasopressive hormones, thus provoking contraction of coronary artery smooth muscle cells
and favouring the development of arrhythmia.
Die Rolle von Magnesium bei Herzerkrankungen
Zusammenfassung: Aus der gegenwärtigen Kenntnis der physiologischen und biochemischen Wirkungen des
Magnesiums (Mg24") auf das Herz werden einige Aspekte der Päthogenese von Herzkrankheiten referiert.
Verschiedene Autoren fanden bei Menschen in Gegenden mit weichem (Mg2"H-armem) Trinkwasser eine
Abnahme des Mg2+-Gehaltes im Myocard ohne signifikante Änderungen des Mg2+-Gehaltes im Serum und
Skelettmuskel. Die Bedeutung dieser Befunde bleibt ungeklärt. Bei Patienten kommt es während eines Myo-
cardinfarktes im Myocard auch in den nichtinfarzierten Bereichen zu einer Abnahme des Mg24~-Gehaltes und
im Serum zu einer vorübergehenden Abnahme der Mg24"-Konzentration.
Diese Wirkungen lassen sich mit einer Katecholamin-bedingteii Mg2"1"-Abgabe aus den Myocardzellen erklä-
ren. Die Abnahme der Mg^-Konzentration im Serum wird auf eine Katecholamin-bedingte vermehrte
Mg2+-Ausscheidung durch die Niere und/oder eine vermehrte Mg2+-Aufnahme in Adipocyten zurückge-
führt. Durch die vermehrte Lipolyse kann Mg2+ vorübergehend an freie Fettsäuren in Adipocyten gebunden
werden. Bei einer verminderten Mg2"^Konzentration im Serum kann die Wirkung von Katecholaminen und
vasopressiven Hormonen auf das Herz verstärkt werden. Dies kann eine Kontraktion der Koronararterien
hervorrufen und das Auftreten einer Arrhythmie begünstigen.
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Introduction
Magnesium (Mg2+) is the second most common in-
tracellular cation. It is known to activate nearly 300
enzymes. By reacting with phospholipids, nucleic
acids and cell membranes Mg2+ influences their
structure and stability. By direct action via Mg2+ de-
pendent enzymes and ATP and by indirect effects
via alteration of Ca2+ influx, Mg2+ modulates the
tension development in skeletal, smooth and cardiac
muscle.
In the last decade several reviews have been con-
cerned with the relevance of Mg2+ in cardiac disease
(1-7). Nevertheless, the role of Mg2+ qualitively
and quantitatively is not fully appreciated by most
physicians, while some are inclined to overemphas-
ize its importance. Despite the ready availability of
serum Mg2+ determinations e.g. by atomic absorp-
tion spectrophotometry, such measurements are not
routinely performed. The consequence is that essen-
tial data are pften lacking. The aim of the present
review is to elucidate some physiological and bio-
chemical actions of Mg24" in the mechanism of cardi-
ac disease.
Possible Effect of Mg24" Intake from Tap Water
Cardiovascular Disease
In epidemiological studies, it has been suggested that
there is a relationship between water hardness of lo-
cal supplies and mortality rates from cardiovascular
diseases. Since the early 1960s several authors have
established a negative correlation between water
hardness and myocardial infarction (8—16). Howev-·
er, the correlation coefficients, although statistically
significant, were small. Subseqüent reviews of the
principal epidemiological studies revealed that in ap-
proximately 30 to 50% of the papers such a relation-
ship could not be detected (16, 17). This is not sur-
prising, if one realizes
1) that some water analyses were made only at the
waterworks and not at the user's tap where re-
sults can be quite different due to contact with
conduit materials of the distributing network; al-
so
2) the same hardness can be caused by differing
proportions of Ca2H" and Mg2+; moreover,
3) deaths were registered at the place of residence,
and exposure at the place of work, where large
quantities of different drinking water may be
consumed, was not taken into consideration.
It should be recognized that the soft water effect is
not necessarily a cardio-specific one. It has been re-
ported that the prevalence |of cerebrovascular dis-
eases (9), of bronchitis and infant or adult mortality
(12, 18) were higher in soft than in hard watef re-
gions. Furthermore, the prevalence at birth of con-
geiiital malformations of the central nervous System
was negatively correlated with total water hardness
(19).
In Europe cardiovascular diseases teiid to inefeäse
from south to nörth while wäter hardness decreases
in the same direction (12, 20). In the USA incideiice
of cardiovascular disease and water hardness are
lowest in the northern and midwest plains and high^
est in the southeast (20). it is clear that latitüde per
se is not the factor responsible for the rate of my-
ocardial infarction. Perhaps some of the disciepan^
cies in investigatiöns of wäter hardness and mortality
from myocardial diseases may be attributed to a ge-
netic factor since there is a stfoiig eörrelation be-
tween blood group 0 and cardiovascular mortality
(2l).
Several authors have favored Mg2+ äs the cardioprö-
tective water factor (2, 15, 16) and emphasized the
importance of the Ca2+/Mg2+ ratio in food (14). In
some presentations, the main afgumeiit is that
1) chronic Mg2+ deficient rats develop multiple fo*
cal cardiac necroses (22-^24) and
2) data have beert presented shpwing that, generally
in our western world the Mg2+ content of refined
food is lower than in more primitive agricultural
societies (2, 15).
When the individual Mg2"1" intake from food is low,
e.g. 200-250 mg, then the additional daily Mg2H" iü-
take in Mg2"*" rieh, hard water regions, e.g. 50mg,
may have a "cardioprotective" effect while in soft
water regions a chronic Mg2"1" defiöiency is likely to
develop (2, 14, 16, 25). Unfortunately, it is difficult
to evaluate the true human reqüirement öf Mg2*:
depending age and protein intake the values giv-
en by various authors ränge from 0.1 to 0.4 mmpl/kg
per day (26,27). This rnay be partially due to consid-
erable individtial Variation in intestinal absöirption
and renal excretion of Mg2+. För instance, patients
with tetanic syndfome and normal Mgi+ intake via
food and tap water were cured only when receiving
an additional 200—600 mg Mg2+, which inereased
serum Mg2+ by approximately 10% (28).
To proof the soft water Mg2+ deficiency Iheory, se-
rum levels of Mg2+ of a fepresentative population of
soft water and hard water regions should be com-
pared. Only one study was coneerned with this ques-
tion. No difference in serum Mg2+ and Ca2+ was
found for both populations. Also, bone mineraliza-
tion measured by X-rays was the same (29). This
finding is not very surprising, becamse the Standard
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deviation of Mg2* determinations makes it difficult
to detect a decrease from the normal level in the
ränge of < 10% äs is the case in mild Mg2"1" deficien-
cy. The broad Variation of normal serum Mg2* levels
may be caused not only by individual Variation in in-
take and intestinal absorption but also by Variation
in exposure to stress. For example in man and rats,
noise stress rapidly changes serum Mg2"1" concentra-
tion (30). Thus, comparison of serum Mg2* in epide-
miological studies of populations from soft and hard
water areas is of limited value (see below).
In growing young rats with chronic Mg2* deficiency
cardiac Mg2* is lower than in normally fed rats of the
same age. However, this effect is only significant
when serum Mg2* is reduced below a threshold con-
centration of 0.6—0,7 mmol/1 (31). Nevertheless, in
humans some evidence in favour of the soft water
Mg2* deficiency theory might come from analysis of
postmortem cardiac Mg2* content of subjects who
were residents in Mg2* rieh, hard water localities or
Mg2* poor, soft water regions. In a Canadian study
cardiac tissue of victims from accidental death was
analysed in order to compare residents in regions
with either 29.4 ppm or 2.8 ppm Mg2* in tap water.
As can be seen in table l it was found that in the soft
water regions cardiac Mg2* was 7% lower than in the
hard water regions (36). Also in accidental death the
Mg2* content of coronary arteries was lower in soft
water regions (11). One wonders why Mg2* in heart
muscle or coronary arteries is reduced in soft water
regions while there is no reduction in serum Mg2*
concentration (see above)4 Evidence has been pres-
ented, that in some patients there may be a decf ease
in skeletal muscle Mg2*, while the serum Mg2* value
is normal (43, 44). However, in these analyses colla-
gen was not determined in the sample. An apparent-
ly opposite result was reported in another study from
England. Here water hardness was determined
mainly by Ca2*, while the Mg2* content of tap water *
was 5 mg/1 and 2 mg/1 respectively, which does not
greatly affect the Mg2* intake from water. Under
this condition the Mg2* content of cardiac tissue
from soft water was 15—26% higher when compared
with hard water (37, 45). On the other hand, in a
study from the same country, using a large nümber
of samples from 28 areas there was no evidence of
any association between the tissue levels and the lev-
els of Mg2* and Ca2* in tap water (41). This discre-
pancy cannot be explained.
In summary the soft water Mg2* deficiency theory
. remains a rather unsettled issue. When Mg2* intake
by food is low, due to individual eating and cooking
habits, then the Mg2* content of drinking water may
be critical in preventing a chronic low grade deficien-
cy.
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Mg2* Content of Heart Muscle after Myocardial In-
farction
In dogs 8—11 hours after permanent coronary liga-
tion the Mg2* and K* content of the left infarcted
ventricle were reduced by approximately 49% and
47% respectively. In the right non-infarcted ventri-
cle the decrease of Mg2* and K* were in the ränge of
only 7% and 2%, respectively, which was not signifi-
cant (46). In similar experiments with rats, 24 hours
after coronafy ligation the Mg2* and K* content of
the injured region was reduced by'50% and 45%,
respectively while there was no change in the re-
maining healthy myocardium (24). In another study
with coronary ligated dogs only the cation changes of
the necrotic area were reported. Within one hour,
the Mg2* content dropped by 23% and remained
constant at this level over the next hours (47). Also,
after a period of 3 hours of experimental haemor-
rhagic hypotension of dogs the Mg2* content of the
right and left ventricular myocardium was lowered
by 27% and 30% respectively (48). Furthermore, in
asphyxic heartS of guinea pigs, the Mg2* content was
reduced by 31% compared with control hearts after
one hour (49). In another type of experiment, using
dogs, the effect of transient ischaemia followed by
reperfusion was investigated; again there was no
change in cellular Mg2* and Ca2* of the uninvolved
tissue. In the infarcted posterior papillary muscle a
23% fall of Mg2* and a more than 10 fold decrease
of Ca2* was registered (50).
The Mg2* content pf normal human heart deter-
mined by several authors is in the ränge of 200
mg/kg wet weight (tab. 1). Table 2 shows the relative
changes in the concentrations of Mg2*, K* and Ca2*
in patients who died of myocardial infarction, äs ver-
ified by post-mortem examination. Essentially the
same ehanges were found äs obtained in experimen-
tal infarction with animals. However, in contrast to
studies with experimental animals the electrolyte
content of the remaining healthy regions of the hu-
man heart was also changed. The Mg2* and K* con-
tent of the noninfarcted tissue was reduced (3, 34—
36, 39-42) and that of Ca2* was increased (36, 39,
4l, 42). The percent Mg2* loss of the uninfarcted left
ventricle varied between 12% and 33%. Ignoring
the fact that the authors used different reference
points, it can be said that in the 8 cited studies with
653 cases the average decrease of Mg2* in the nonin-
farcted region of the left ventricle and apex was
about 18%.
In the infarcted necrotic areas the decrease of my-
ocardial Mg2* was more pronounced (42). The loss
of Mg2* from noninfarcted areas has been termed
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Tab. 1. Postmortal Mg2* concentration in normal human heart.
Abbreviations: LV = left ventricle, RV = right ventricle, V = ventricular, A = apex, d.w. = dry weight, w.w. = wet weight,
n = number of determinations.





















































































































Tab. 2. Change of postmortal electrolyte concentration in human heart after ischaemic heart death. Sarriples were taken from non?
ischaemic areas.
Abbreviations: w. w. = wet weight
d. w. = dry weight
n. d. = not determined
SIHD = sudden ischaemic heart death
SNIHD = sudden non ischaemic heart death
(myocardial degeneration)
NHD = non heart death
IHD = ischaemic heart death
AT = acute trauma
LV = left ventricle
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"cardiospecific", since, at least in skeletal muscle or
diaphragm of the sarne cases, there was no change in
the Mg2+ content (32, 34, 36).
Some of these results suffer from methodological
shortcomings. These are äs follows:
1) Most of the authors related their analyses to wet
weight instead of dry weight, despite the fact that
it is known from animal infarction experiments
that the water content of the heart is increased by
7.5% äs a result of an interstitial oedema (51).
Thus, in cases with oedema the relative loss
found with wet weight äs the reference point may
overestimate the trüe change in cellular Mg2"1".
2) Some authors did not specify exactly the region
of the heart from which specimens were taken.
Others gave no localization at all, or indicated
only apex or ventricles äs origin. It is known that,
in man, the left and right ventricle have different
Mg2+ concentrations (33,38,42). Also in the dog
the atria and various parts of the ventricles have
different Mg2+ concentrations (50, 52, 53). In
dogs after injection of 28Mg2"t", the left ventricle
exhibited a higher activity than the right one, and
the highest intracardiac activity was found in the
septum (54). Accoirding to Page & Polimeni (55),
in the rat heart, total Mg2+ is exchanged almost
completely with one uniform rate constant so
that one can conclude that a higher radioäctivity
corresponds to a higher Mg2H" content. Unfortu-
nately, the difference of Mg24" content in the var-
ious regions of the heart is in the same ränge äs
the amount of Mg2+ lost after myocardial infarc-
tion. Thus, for the sake of comparisön, samples
should be taken from the same region.
3) Tissue samples from noninfarcted regions have
been analysed for Mg2"4" without histological ex-
amination of an aliquot. However, even äs a re-
sult of prior subclinical ischaemic episodes, there
may be multiple small scars within the tissue
which cannot be seen by gross inspection. Since
connective tissue has a lower Mg2+ content than
eardiac muscle, part of the described Mg2+ loss
after infarction might be due to "dilution by col-
lagen fibres" (24).
Although one could wish for a more exact determi-
nation of the decrease of Mg2*, it is confirmed that
myocardial infarction results in lowered Mg2+ con-
tent of noninfarcted regions. It is not known whether
we are dealing with a loss of Mg2+ preceeding the
infarction and/or with Mg2"1" loss äs a consequence of
the various hormonal and metabolic reactions that
occur during myocardial infarction.
When myocardial Mg2+ is already lowered before in-
farction it would indicate a Mg2"1" deficiency, which is
perhaps exaggerated by soft water and/or a low
Mg2+ intake. It is known that in rats with chronic
Mg2+ deficiency, heart äs well äs muscle Mg2+ is de-
creased in the presence of hypomagnesaemia. Also,
tissue K+ is lowered while that of Ca2"1" and Na* are
increased (56—61). As can be seen in table3 in
Mg2+ deficiency the relative loss of cardiac Mg2+
varies between 2% and 20%. Since some of the re-
pörted Mg2"1" changes are at borderline significance
one should not be surprised that the relative loss of
Mg2+ from heart and skeletal muscle differed some-
what with the various authors. While some found a
preferential (56, 59) or almost equivalent loss of
Mg2+ from heart and skeletal muscle (57, 58), others
have reported a preferential loss of Mg2+ from skele-
Tab. 3- Loss of Mg2"1" from various Organs of the Mg2+^deficient rat in percent of controls. The reduction of skeletal muscle Mg2+ content
seems to be more pronounced at the lowest serum Mg2+ concentrations.
Abbreviations: w.w. = wet weight, d.w. = dry weight, * calculated from fig. 11 of I.e. (59),
Aiithor
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tal muscle (60). It should be noted that in Mg2* defi-
ciency no significant loss of skeletal Mg2+ was ob-
served in adult rats (62).
Apart from experimental variability, e. g. in ashing
the samples, variations in results are perhaps caused
by the interplay of factors such äs cjifferent rates of
physical activity and stress from noise, temperature
and social factors etc. plus the different age and
growth rate of the animals äs well äs duration of
Mg2+ deficiency. Thus one can state that during
Mg2+ deficiency, at least in young rats, Mg2+ loss is
not cardiospecific. In man, Mg2+ deficiency was
found with (-11 %) and without a decrease of skele-
tal muscle Mg24" (63) but no data on cardiac Mg2+
content are available. In myocardial infarction, no
loss of Mg24" was found in skeletal muscle (see
above). Furthermore, the relative decrease of Mg2"1"
in the noninfarcted areas was the same in härd and
soft water regions (36). Therefore, at present more
facts are needed to decide whether a cardiac lack of
Mg2* is a risk fäctor for myocardial infarction. How-
ever, when serum and muscle Mg2+ content are
found to be normal in patients with myocardial in-
farction, a preceeding Mg2+ deficiency can be ex-
cluded.
Effect of Catecholamines on Cardiac Mg2+ Content
It is well established both in man and in animals that
myocardial infarction is accompanied by increased
catecholamine concentrations in blood and urine.
The increase in catecholamine concentration is relat>
ed to the severity of myocardial infarction and seems
to precede the major complications of infarction (for
review see I.e. (64)).
One of the various actions of catecholamines is to
alter cardiac electrolyte inetabolism by Stimulation
of a- äs well äs ß-receptors. In experiments with rats
and dogs injection of high doses of the ß-agonist iso-
proterenol or of the -agonist phenylephrine and al-
so of the a- and ß-active adrenalin produced a loss of
cardiac Mg2+ in the ränge of 12-39% (23, 65-68).
The loss of Mg2+ was complete within 0.5-1 hours
(67) and was shown to be "cardiospecific" since in
skeletal muscle, liver, erythrocytes and bone no ef-
fect could be observed (23, 67). The cardiac Ca2+
content showed a more pronounced increase of 2-3
fold (23, 68, 69) but the time course was different
for loss of Mg2+ and gain of Ca2+,.indicating that
these two effects are not coupled, äs already known
from experiments on 28Mg2+ transport (70). It
should be noted that these changes in electrolyte
content could be prevented by the specific a- or ß-
antagonists (23, 24, 65).
Most interestingly a linear relationship between the
increase of urinary catecholamine excretion and al-
terations of cardiac Mg2* and Ca2+ could be estab-
lished in rats that were Mg2"1" deficient and noise
stressed (31).
In animal experiments, injection b'f catecholamines
also rapidly produced disseminated myocardial ne-
croses (23, 24, 65) and/or cardiac hypertfophy (for
review see I.e. (71)). Initial lesioiis were partly re-
versible. However, there was no quantitative corie-
lation between the deerease in Mg2"1" content and ex-
teiit of necroses, älthough the effects on Mg2"1" and
Ca2+ content were additive (68).
It should be noted that the alterations in intraceihilaf
electrolyte concentrations always preceded the mor-
phological changes (23, 65). When MgCl2 or KC1
was given shortly before isoproterenol injection, the
electrolyte changes äs well äs the morphological al-
terätions could be prevented (69).
Somewhat different results were obtained when the
effects ofendogeneous arid synthetic catecholamines
were compared, After the injection of isoproterenol
the extent of cardiac necroses was the same in nor-
mal and Mg2+ deficient rats (68), On the other hand>
when endlogeneous secretion of epinephrine and
norepenephrine was incfeased by cold exposure (61,
72) or by heat or restraint (72) Mg2* deficient rats
responded with a higher incidence of myöcäfdiäl ne-
cröses than normal rats. The stronger reaction in
Mg2+ deficient rats was also found after injection of
epinephrine (73). These results demonstrate that
experiments with injected isoproterenol may not
represent the endogeneous physiologicäl stress reac-
tion.
An understanding of the mechanism whereby ca-
techolamines alter cardiac electrolyte content is be-
ginning to evolve. In the case of Mg2*, both inhibited
influx and accelerated efflux can be induced. In elec^
tirophysiological experiments, it has been shown that
the rat heart may have a Mg2"l"-specific chännel that
is distinct from the Ca2+ channel. Isoproterenol was
shown to inhibit Mg2+ influx through its channel
(74). However, for criticism see L c. (75). Fuither ev-
idence for an effect of isoproterenol on Mg2+ uptake
came from experiments with another mödel. In lym-
phoma cells, isoproterenol inhifeited ?8Mg2+ influx
but not that of 45Cä2+, an effect that could be coun^
teracted by propranolol. The isoproterenol-induced
Inhibition of 28Mg2+ influx was mediäted by the same
receptors that activate ädenylate cyelase. It remains
to be ascertained whether the complete ädenylate
cycläse is necessary to close the Mg2^ channel, or
whether this effect is produced by ^ar protein coupled
J. Clin. Chem. Clin. Bioohem. / Vol. 21, 1983 / No. 5
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to a component of the enzyme System. Interestingly,
cAMP and protein kinase were not involved in this
mechanism (70). In the heart, a short time after in-
jection of isoproterenol, the ATP and creatine phos-
phate content is considerably decreased (69, 71). In
this process the concentration of free Mg2"1" will in-
crease and Mg2"1" can thus be released from the heart






Fig. l. Regulation of net Mg2* fluxes. Feed-back Inhibition of net
Mg2"1" influx at a physiological intracellular Mg2"1" concen-
tration ( >)· Induction of net Mg24 efflux when in-
tracellular frce Mg2* is increased by breakdown of ATP.
Abbreviations: [Mg2"l"]0 = concentration of free extracel-
lular Mg24, [Mg2+]i = concentration of free intracellular
Mg24, MgX,· « intracellular bound Mg2*
The isoproterenol-induced increase of cardiac Ca2"1"
content is brought about by binding of the catechol-
amine to the ß-receptor, with subsequent activation
of the adenylate cyclase. The increased cAMP acti-
vates a membrane-bound protein kinase that phos-
phorylates calciductin and thereby induces the spe-
cific increase of Ca2+ influx (76), either by chanelling
or gating.
When we consider the pathophysiological relevance
of a lowered content of cardiac Mg2+ it must be re-
membered that the biological effects of Mg2"1" depend
on its ability to form chelates, ATP being the most
important intracellular ligand. Bound and free cellu-
lar Mg?+ form a Mg2* buffef that maintains a con-·
stant concentration of free Mg2+ (for review see 1. c.
(77)). On the basis of indirect evidence, it has been
assumed that cardiac free Mg2+ may be in the ränge
of l mmol/1 cell water (78). Recently, using 3|P nu-
clear magnetic resonance, a value of 2.5 mmol/1 has
been obtained for heart (79). With a Mg2"1" sensitive
microelectrode a free Mg?+-concentration of 3.1
mmol/1 has been determined in ventricular muscle of
the sheep and ferret (80). It is the total and not the
fcee Mg2"1" that has been measured until now in nor-
mal and diseased heart muscle of man. An 18% de^
crease of total Mg2"1" äs is seen äfter myocardial in-
farction in the noninfarcted areas is to small to re-
duce free cellular Mg2* enough to affect metabolism,
since the enzyme activity changes with pMg. Indeed,
it has been shown recently by means of 31P nuclear
magnetic resonance that, after ischaemic arrest of
the heart for up to 35 min, free Mg2"1" remained con-
stant at 2.5 mmol/1 (79). Consequently, factors other
than a change of free intracellular Mg2+ are respon-
sible for the severe alterations of cellular function
after infarction. These could be the decrease in high
energy phosphates and pH and the metabolic conse-
quences of these events.
Furthermore, besides alterations of cytosolic Na+
and K"*", the cytosolic Ca2+ concentrations may be
increased and thereby involved in cardiac dysfunc-
tion. At present, this parameterhas not been deter-
mined. The measured increase in total Ca2+ of the
heart is due, in part, to an increase in the extracellu-
lar Ca2+ content. This is the result of enhanced ex-
tracellular fluid volume which has not yet been de-
termined under these conditions. Furthermore, ac-
cumulation of Ca2+ by necrotic cells, together with
their eventual calcification must be considered. Also,
intracellular Ca2+ accumulation by living cells is en-
hanced, and the distribution of Ca2+ in these cells
may be changed, e. g. an increased intracellular ac-
cumulation in "mitochrondria and particularly in sar-
coplasmic reticulum may occur.
In summary, animal experiments show that cate-
cholamines induce a loss of cardiac Mg2"1" and a gain
of Ca2+. The alterations were more pronounced in
cases of Mg2+ deficiency.
Regulation of Myocardial Mg2+ Content
The above mentioned alterations in myocardial Mg2+
content äs observed after myocardial infarction, or
produced by high levels of either endogenous or syn-
thetic catecholamines may be explained by the fol-
lowing regulatory mechanism (see fig. 1).
Intracellular free Mg2+ is in equilibrium with bound
Mg2+ (MgXi), which accounts for up to 90% of total
intracellular Mg2+. Thus intracellular Mg2"1" is buf-
fered in the ränge of pMg 3 so that Mg2+ dependent
enzyme activation is optimal or nearly optimal (for
review see I.e. (77)). Intracellular free Mg2+ concen-
tration may also be held constant by feedback Inhibi-
tion of net Mg2+ influx. Therefore total intracellular
Mg2"1" cannot be elevated above the physiological
välue when the extracellular concentration of free
Mg2+ is increased.
However, total intracellular Mg24" can be altered by a
change in the concentration of Mg2+ binding ligands,
i.e. when the ATP concentration in ascites tumour
cells is enhanced by incubation with adenosine, and
more Mg2+ is bound to ATP (81), or when lipolysis
in fat cells is increased and water insoluble Mg2+
soaps are formed (see below), thereby causing a
J. Clin. Chem. Clin. Bioqhem. / Vol. 21, 1983 / No. 5
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transient reduction in the concentration of intracel-
lular free Mg2·*". Under these conditions, a net up-
take of Mg2+ takes place until the intracellular free
Mg2* reaches its original value. Thus total cellular
Mg2+ increases.
On the other hand, there is no net efflux of Mg2+
from the cell when extracellular Mg2+ is omitted or
complexed, indicating that there is no single steady
state equilibrium of net Mg2+ influx and Mg?+ efflux.
A net efflux Mg2+, with a consequent reduction of
total cadiac Mg2+, occurs only when the intracellular
concentration of free Mg2+ is transiently increased
by breakdown of ATP; this is observed after injec-
tion of isoproterenol, during ischaemia or after my-
ocardial infarction. As a consequence the intracellu-
lar free Mg2+ concentration remains constant (79).
Serum Mg2+ after Myocardial Infarction
When Mg2+ or qther intracellular substances are lost
from the ischaemic heart muscle they should reach
the circulation. In fact, in dogs with coronary artery
ligation the concentrations of Mg2+ and K+ in plas-
ma of the coronary sinus were found to rise by 24%
and 12% respectively 8-11 hours after ligation
(46). However, when the experiment was repeated
and Mg2+ was measured in peripheral serum, no in-
crease but rather a decrease was detected after 1-4
hours, and this was normalized after 12—24 hours
(47, 82).
Determination of serum Mg2* in patients with my-
ocardial infarction has yielded no uniform results
(tab. 4). Some authors did not detect any change in
Tab. 4. Change of serum Mg2+ after myocardial infarction.
n = number examined
Author Ref.
Brown et al. 83
Hughes & Tonk 84
HyattetaL 85
Nath et al. 82
Abraham et al. 86
Lund et al. 87
Petersen et al. 88
Gouldzlal. 89
Spetch et al. 90
Dyckner 91


















































the concentration of serum Mg2+ (83, 85, 87, 89,
90), and some found ort the 12th day (90) a transient
increase which is almost certainly not related to the
changes observed during the first hours after infarc-
tion. Nevertheless most of the authors found a de-
crease of serum Mg2"1" several hours, after the onset of
myocardial infafctiori. When we disregard ä stüdy
with values obtained in the fürst and second wedc af-
ter myocardial infarction (82) then 7 groups with a
total of 516 cases of myocardial infarction reported a
decrease of serum Mg2+ by 3.8 to 12.8% with a
rnean value of approximately 9%. In a qüite recent
investigation the patients were divided into two
groups: one group with uncomplicated infarction
and another grpup with complicäted infarction, e.g.
with severe ventricular ectopic beats, ventricular ta-
chycardia, arrhythrnia, and ventficülar fibrillatipn.
Lowered serum Mg2* values were only found in the
group with complicäted myocardial infarction (91,
94). In other words: if, at the time of admission for
myocardial infarction, serum Mg2"1" is iowered, then a
mofe severe development with cardiac arrhythmias
must be expected. Within 2-3 days the Iowered
Mg2+ values retürn to a normal level (93).
The contradictory results, ranging froin no change
versus decrease of serum Mg2+ might be explained
by a difference in clinical protocols. The time lag be-
tween onset of myocardial infärction and determina-
tion of Mg2+ varies between "admission'' to the hos-
pital and the second week after infaiction. Fuither-
more the relätionship between time of blood ;sam-
pling and treatment of the patient is not recorded.
After myocardial mfarctioii, serum Mg2+ should be
measured äs early äs possible and continued at short
time intervals for the first däy. This might elucidate
the course of post-infarct changes in serum Mg2"1".
What explanation cän be offered to explain the
change in serum concentration after myocardial in-
farction? In a first phase the Mg?+ released from in-
farcted and noninfarcted areas of the heart should
lead to a transient increase in serürn Mg2"1" concen-
tration. However, the amount of released Mg2+ is
small, the egress takes some time and some Mg2+
may be lost by urinary excretioii during this time.
Considering all these factors and calculating the dis-
tribution of Mg2+ over the extracellular fluid, a sig*·
nificant increase in serum Mg?+ is not bound to öc-
cur, but it inay do so. Moreover the individuäl prein-
farction serum Mg2:f concentration is usuaily un-
known.
In a later phase most aüthors observed a decrease of
serum Mg2+ concentration, One possible explana-
tion is an increased renal loss of th$ Ration following
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the increased secretion of catecholamines, probably
through an indirect effect in which catecholamine
suppression of Insulin secretion (for review see I.e.
(64)) raises blood glucose. In the rat it has been
shown that nonglycosuric hyperglycaemia, produced
by an infusion of glucose, enhances urinary Mg2+ ex-
cretion (95). In man, ingestion or infusion of glucose
likewise has been found to increase renal excretion
of Mg2* (96, 97). In parallel to this in diabetic pa-
tients the urinary Mg2* excretion rate was found to
rise with increasing fasting blood glucose and gluco-
suria, leading to hypomagnesaemia (98). In rats with
experimental myocardial infarction both hypermag-
nesaemia and increase in urinary excretion of Mg2*
have been detected (24). However, in man with my-
ocardial infarction we know of no systematic investi-
gation on renal Mg2* excretion. In the only study we
are aware of, urinary excretion of Mg2* showed a
tendency to decrease after infarction (94). However,
the authors collected urine over a period of 24 hours.
Within this timespan serum Mg2* has been known to
increase towards normal levels (93). To ascertain
that there is really no change in renal Mg2* excre-
tion, Information on urinary Mg2* and on glomerular
filtration rate during the early post-infarct period is
urgently needed when serum Mg2* might be in a
state of transient decrease.
There may be a further explanation for the post-in-
farct decrease in serum Mg2* concentration. Flink
et al. (93) correlated the decrease of serum Mg2*
with a concomitant increase of free fatty acids. The
rise in free. fatty acid concentration is explained by
an increased lipolysis which is induced by the en-
larged catecholamine secretion involyed in infarc-
tion. The same observation, a low Mg2* concentra-
tion at increased free fatty acid concentration in se-
rum was also found at ethanol withdrawal in dogs
(99) and after infusion of adrenalin in ewes (100).
Since the free fatty äcids are able to bind Mg2* it has
been assumed that serum Mg2* is thereby lowered
(93). This must be doubted. Atomic absorption
spectrometry, used by the authors, analyses both
free and bound Mg2*; it does not detect changes in
the ratio of free to bound Mg2*.
Perhaps a more reasonable explanation for lowering
of total serum Mg2* during increased lipolysis is an
increased binding of Mg2* by free fatty acids within
the adipocytes. In vitro experiments with adipocytes
support this view. Intact adipocytes showed an in-
creased Mg2* uptake aftef treatment with adrenalin
(101). This suggests increased intracellular binding
of Mg2*. The intracellular uptake of Mg2* is a ß-ad-
renergic effect and it is coupled to lipolysis (102). It
must be realized that a small increase in Mg2* uptake
by the adipose tissue is sufficient to produce the
small decrease (-8%) in serum Mg2* concentration.
These observations suggest the formulation of the
following hypothesis. Increased catecholamine re-
sulting from myocardial infarction causes loss of
Mg2* from the myocardium. Lipolysis is increased
leading to an increase of free fatty acids, not only in
serum, but also in adipose tissue. Therefore uptake
and binding of Mg2* by adipose tissue is increased.
Due to different amounts of adipose tissue among
individuals the decrease of serum Mg2* might be dif-
ferent from patient to patient. The ratio of adrenal-
in: noradrenalin released in infarction might be dif-
ferent from patient to patient. In isolated subcutane-
ous adipocytes the relative potencies of catecholam-
ines with ß-adrenergic activity were: isoproterenol
> adrenalin > noradrenalin (103, 104). Therefore,
the decrease of serum Mg2* may be more pro-
nounced at a high ratio of adrenalin: noradrenalin.
Furthermore in human adipocytes -agonists inhibit
lipolysis (105—107) and there are different amounts
of a- and ß-receptors in adipose tissue from different
areas of the body. Thus adipose tissue from some
areas can be insensitive to the lipolytic effect of ca-
techolamines (108). Moreover the lipolytic effect of
noradrenalin in human tissue increased with the di-
ameter of fat cells, with either obesity or fasting
(109). Also, a variable antilipolytic effect of insulin
must be considered, since suppression of insulin se-
cretion in myocardial infarction (64) will vary with
the amounts of catecholamines released. Interaction
of these factors may explain why in some patients
with myocardial infarction serum Mg2* was found to
decrease while it was unchanged in others.
That these mechanisms may really operate in vivo
may be inferred from experiments with rats. In this
spedes the relative potencies were isoproterenol:
noradrenalin : adrenalin = 10 : 2 : l (110). In con-
trast to the observations obtained in ewes adminis-
tration of catecholamines in rats caused an increase
of serum Mg2* (111). Interestingly, in rats, the in-
crease of serum Mg2* concentrations was 5 times
higher by s. c. injection of phenylephrine than by iso-
proterenol, although both substances caused the
same release of Mg2* from the heart (68), because
isoproterenol produced lipolysis and Mg2* uptake
into adipose tissue.
In summary, we explain the decrease of peripheral
serum Mg2* observed after myocardial infarction by
increased uptake and binding of the cation by adi-
pose tissue äs a consequence of increased lipolysis.
In addition increased urinary excretion may be in-
volved in the postinfarct decrease in serum Mg2*,
J. CJin. Chem. Clin. Biochem. / Vol. 21, 1983 / No. 5
258 Ebel and Günther: Role of magnesium in cardiac disease
provided that the glomerular filtration rate is not re-
duced beyond a critical level.
Cardiomyopathy
Human cardiomyopathy or myocardiopathy is a
term often used for a rather heterogerieous group of
heart diseases that are not secondary to coronary
heart disease, rheumatic or congenital malformation
of the heart and vessels, or arterial or pulmonary hy-
pertension. As regards terminology and classifica-
tion the literature is still rather equivocal (112—
114). Although there are differences in morphology
regarding various forms of this disease the follpwing
alterations may be observed: cardiomegaly, endo-
cardial thickening, a mural endocärdial thrombus,
myocardial scars without gross alterations in the co-
ronary vessels. Light and electron microscopic exam-
ination reveals increased number of mitochrondria
of variable size that are swollen and show ruptured
cristae. The myofibrils are hypertrophic, often par-
tially fragmented and in disarray. The T-tubules of
the sarcoplasmic reticulum are swollen. Increased
numbers of degenerative organelles, lysosomes, au-
tophagic vacuoles and lipofuscin pigment granüles
are present.
The aetiology and pathogenesis of the so-called
primary or idiopathic cardiomyopathy are unknown.
The secondary cardiomyopathies include infectious
myocarditis (viral, bacterial and others), metabolic
cardiomyopathies (e.g. äs a consequence of thyroid
dysfunction), glycogen storage and nütritional defi-
ciencies of vitamins and proteins, toxic cardiomyo-
pathies and several other forms. Mg2+ deficiency
may be involved in some of these conditions, e. g. in
alcoholism (115), in hyperthyreosis (116, 117) and
in protein malnutrition (118). However, äs yet, there
is no proof that Mg2"1" deficiency is really involved in
the pathogenesis of some of these cardiomyopathies.
An experimental model for this disease is the heredi-
tary spontaneous cardiomyopathy in inbred hamster
strains. These hamsters develop myocardial degen-
eration and myolysis similar to human cardiomy-
opathy between the 30th and 40th day of life. Their
hearts exhibit a decreased content of Mg2+ and an
increased content of Ca2+ before the lesions develop.
The decreased myocardial Mg2+ content does not
persist, but the Ca2+ content rises markedly between
the 60th and 80th day. The change in Na+ and K+
content is small and not significant (119). Hamsters,
when 30 days old and in the prenecrotic stage are
more sensitive to isoproterenol-induced Ca2+-up-
take (120) and necrosis (121) than normal animals.
Ca2+ accumulation and myocardial necrosis during
both the prenecrotic and the cardiomyopathic stage,
could be prevented by the Ca2* antagonist verapamil
(120, 121). Also, high doses of Mg2* had a prophy-
lactic effect against ceihilar Ca2+ accumulation and
oft the development of necrosis, probably by a Ca24"
antagonistic effect (122), Although fliuch remairis to
be established, the hamster cardiomyopathy proba-
bly is caused by a defect in sarcolerrimal Ca2+ trans*
port; this in turn leads to increased Ca2"1" uptäke and
damage of heart mitochondiia aiid Gonsequently to a
deficient energy supply to the cell with ensuing ne-
crosis (123).
Subjective and objective improvement (124) düfing
chronic verapamil therapy suggests that a mecha-
nism similar to that in the animal may be involved in
human cardiomyopathy. Also of significänce is the
increased membrane permeability and cytosolic
Ca?+ cpncentration caused by viral infection (125).
Perhaps the same mechanism is operative in human
viral cardiomyopathy. It is possible that in all cases
of myocardial cell damage, an incf eäse in intracellu-
lar Ca2+ rtiay be responsible. This tentative conclu-
sion agrees with the hypothesis that in genefal cell
death äs indüced by ischaemia, virüses, radiation,
drugs and toxins is mediated by an increased irre-
versible ceiiular Ca2+ accumulation and an elevated
cellulär Ca2+ concentration (126).
Coronary Artery Spasm
It is now generally accepted that spontaneous fest
angina (Prinzmetars variant angina) is eäused by a
transient coronafy äftery "vasospasm". Recently it
has been suggested that coronary "vasospasm"
might also be involved in a variety of other cardiac
diseases such äs the more common exertionial type
of angina pectoris, myocardial iiifarction and sud-
den-death coronaries. The mechanism of corohary
"vasospasm" appears to be a multifactofial event
which remains to be elaborated; The effect of var
soactive hofmones depends on the kind and number
of agonistic and antagonistic reactiiig receptors in
distinct parts of the eoronary arteries. Activation.of
adrenergic but also öf muscarinergic, serötoriinergic
and histaminergic receptors might be involved. Mo-
reover, prostaglandins and related substances such
äs thromboxaiie Aa might cause eoronary spasm.
Ca2"1" antagonistic drugs have been used suecessfully
to Interrupt aod prevent coronary "vasospasm" (fbr
review see L c. (127—129)). In this review we mainly
focus on the rote of Mg2+ äs the physiölögical Ca2+
antagonist in the regulation of the coronary vaso-
spasm. Not included is the function pf Mg2"1" in the
development of acüte coronary thronabosis or sclefö-
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sis and the relationship of these disturbances to coro-
nary vasospasm.
It is now well established that the contractile activity
of vascular smooth muscle is regulated mainly by the
myoplasmic free Ca2* concentration. The Ca2* con-
trol of the actomyosin System is the final common
pathway by which neurotransmitters, hormones,
drugs, and other ions all exert their influence on vas-
cular smooth muscle. In vivo perfusion of arteries
with a solution that selectively produced only a local
hypermagnesaemia was followed by a decrease in re-
sistance in the forelimb (130, 131), kidney (130,
132), coronary (133), gastric (134), mesenteric
(134,135) and hepatic (136) vascular beds of anaes-
thetized dogs. In the dog, perfusion of the forelimb,
the hind leg, the renal artery and the coronaries with
low Mg2+ blood was without a measurable effect on
the arterial pressure (137, 138). On the other hand
in the same species intraveneous infusion of a salt
solution that reduced extracellular Mg2* concentra-
tion resulted in a significant increase of mean blood
pressure (139). Also, in rats, perfusion of the ileo-
colic artery with Mg2*-free Ringer solution indüced a
reduction of ileocolic vein outflow and a reduction of
arteriolar lumen size (140).
The mechanism of Mg2* indüced vasoconstriction
and vasodilation has been investigated in detail with
isolated blood vessels in vitro. Lowering the external
Mg2* concentration induces a rapid rise in tension
development of isolated aortic Strips of the rat while
an elevation of Mg2* results in lowering of the base-
line tension (141,142). Also, the effects of 0 and 4.8
mmol/1 Mg2* on baseline tension of isolated coro-
nary arteries öf dogs have been docümented. In the
absence of Mg2* tension is increased. The change of
tension is rapid (143).
It seems to be more important that extracellular
Mg2* also modulates hormone and drug indüced al-
terations in baseline tension. In isolated aortic Strips
of the rabbit remöval of Mg2* is followed by a 10—
30% increase of the contractive effect of acetylcho-
line, angiotensin II and K*. On the, other hand the
.. ädrenalin-induced contraction was reduced in the
absence of Mg2* (read from fig. l a.nd' 2 of I.e.
(144)). Qualitatively the same effect, a depression of
the contractile response elicited by supramaximal
doses of adrenalin upon omission of Mg2*, was ob-
served in rat aortic Strips (145). Interestingly, a more
pronounced effect was seen when the contractile ac-
tion of various hormones was tested on different seg-
ments of isolated coronary arteries of the dog. Low-
ering the external Mg2* from 1.2 mmol/1 to zero re-
siilted in an approximate 32—57% increase of ten-
sion produced by angiotensin II. The analogous data
were 81-100% for serotonin and 90-120% for the
-efifect of noradrenalin when assessed against pro-
pranolol (143). In another study on canine coronar-
ies the effect of catecholamines was investigated in
the presence of 1.2 mmol/1 Mg2*. Here, adrenalin
elicited weak contractions in large coronaries, but
relaxation in smail coronaries. However, noradre-
nalin produced relaxation in both large and small co-
ronaries. Propranolol treatment enhanced the adre-
nalin indüced contractile responses of large arteries
and on small arteries it reversed relaxation into con-
traction. Furthermore, the noradrenalin-induced re-
laxation was changed into contraction after propra-
nolol treatment (145). Finally it should be men-
tioned that on aortic Strips of the rat, the lowering of
Mg2* from 1.2 mmol/1 to zero attenuates the con-
tractile response to PGF2a approximately by 75%
(read from fig. 5 of I.e. (146)).
On the other hand, elevation of the extrac'ellular
Mg2* concentration attenuates the contractions eli-
cited by several neurohumoral agents and K*. Rais-
ing external Mg2* above physiologic levels to
4 mmol/1 depressed the tension measured in the
presence of adrenalin, angiotensin, serotonin and K*
by approximately 34 to 69% in isolated rat aorta
(calculated from tab. l of I.e. (140)). Essentially the
same effect was observed with isolated coronary ar-
teries of the dog. The contractile tension that deve-
loped in response to angiotensin II, serotonin,
noradrenalin (in the presence of propranolol) and
K* was decreased by elevation of Mg2* from 1.2 to
4.8 mmol/1 (143). In contrast the contractile re-
sponse of isolated rat aorta to PGF2« was increased
when Mg2* was elevated to 5 mmol/I (146).
Obviously, the mechanism whereby external Mg2*
influences arterial smooth muscle tone is not a direct
one. Experiments with isolated rat aortic Strips have
shown that the contraction indüced by withdrawal of
Mg2* is potentiated by the addition of CaEDTA
which exchanges some Ca2* for Mg2* and thus che-
lates and removes surface Mg2* from the smooth
muscle eells. On the other hand, EGTA which is
known to chelate Ca2* in preference to Mg2* rapidly
feverses the contraction indüced by withdrawal of
Mg2* (147).
Furthermore, it has been demonstrated that in aortic
strips of rabbit and rat the uptake of 45Ca2* is de-
pressed by external Mg2*, but it increases when
Mg2* is withdrawn. That this Mg2* dependent
45Ca2* uptake does not simply reflect extracellular
binding, but is due to intracellular uptake, has been
deduced from experiments with the lanthanum
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nique which removes the Ca2+ bound to the mem-
brane surface. Furthermore, it has been shown that
45Ca2+ efflux is delayed by an increase of external
Mg2*. Based on these findings, it has been proposed
that Mg24" effects vascular smooth muscle tone by
regulating Ca2"1" permeability and exchange (148,
149).
Based on the aforementioned experimental evi-
dence, it has been proposed that Mg2* depletion
might be one of the factors contributing to coronary
vasospasm (143, 150). However, it should be re-
membered that the majority of experiments were
performed in vitro on isolated aortic or other arterial
Strips maintained in blood-free Ringer solution and
mounted under isometric tension. In order to obtain
clear cut results Mg2+ concentrations have been test-
ed far beyond the ränge of hypomagnesaemia usual-
ly observed in patients. For instance, after myocar-
dial infarction, serum Mg2+ is reduced in the ränge of
only 8% (see above); but, in the in vitro experi-
ments, Mg2+ was' lowered by 50-80% (e.g. I.e.
(143)) or was withdrawn completely. Unfortunately,
so far no dose-response curves have yet been pub-
lished to show the effect of various Mg2+ concentra-
tions on the tension of coronary arterial Strips.
Therefore, one cannot assess whether the small
changes of serum Mg2"1" occuring in patients have a
measurable effect on resting tension in vitro. Fur-
thermore, to our knowledge, only one in vivo experi-
ment has shown that perfusion of an artery with
Mg2+ free solution is followed by a narrowing of the
lumen of the corresponding arteriole; however, this
experiment was done in the rat by perfusing the ileo-
colic artery with a Mg2+ free Ringer solution (140)
and not with blood selectively low in Mg2+. It must
be remembered that perfusion of the coronary artery
of the dog with blood selectively low on Mg2+ was
without effect on coronary artery pressure (137). Fi-
nally it should be noted that these studies on coro-
nary artery spasm were performed on healthy tissüe
but not on pathological or diseased tissüe and that
the animals used were anaesthetized. With these lim-
itations in mind one can conclude that the Mg2+ defi-
ciency coronary vasospasm hypothesis needs further
clarification. Perhaps not Mg2+ deficiency per se but
its effect on vasopressive hormones and/or cations
such äs Ca2+ and Na+ may be involved in coronary
vasospasm.
Cardiac Arrhythmie and Electrocardiogram in Hy-
pomagnesaemia
The effect of experimental Mg2+ deficiency on heart
action has been studied primarily in rats and dogs. In
the early phase of Mg2"1" deficiency in young growing
rats, a slight increase of heart rate was observed
which was associated with a transient hyperaemia of
the skin. Subsequently, when hyperaemia spontane-
ously disappeared, the increased heart rate feil con^·
comitantly to a normal rate. Obviou^ly, the transient
tachycardia might be explained by arterial hypoten-
sion düring the hyperaemic phase. In the later hyper-
excitable phase of Mg2+ deficiency, the heart rate re-
mained unchanged. It was only just before the onset
of a convulsion that the heart rate was found to be
markedly depressed, although it slowly returned to
normal after recovery. However, during the brady-
cardiaj a marked arrhythmia was present (151,152).
Mg2+ deficient rats without convulsions did not ex^
hibit changes in the heart rate.(153,154). Neverthe-
less, the Mg2"1" deficient rats terid to have extrasys-
toles (152, 153), Additional electrocardiogram ab-
normalities in Mg2+ deficient rats afe lengthened
P—R intervals and älterations of the S—T segment
(153). In anaesthetized, Mg2+ deficient rats, later in-
vestigators found only a highly significant decrease
of the T-wave amplitude but no change of other am-
plitudes or segments (154). Unfortunately, all the
above mentioned authors did not report whether the
animals exhibited a selective hypomagnesaemia or
were also hypokälaemic and/or hypocalcaemic.
In chronic M^^-deficient dogs, which usually show
no skin hyperaemia, some authors noted no change
of heart rate when compared to animals on control
diets (155,156) whereas others have noted the terid-
ency for intermittent or continuous sinus tachycardia
(158). The electrocardiogräm of the chronic Mg2+
deficient dogs revealed a depression of the R^S^T
segment (156, 157) and widened QRS. Occasional·
ly, ventricular premature beats and bigeminäl
rhythm were also observed (158). Furthermore,
there was a frequent occurrence of T^wave abnof-
malities. A peaking of the T>wave (157,158) äs well
äs a flattened or inverted negative T-wave (155,
156) was reported. Since peaking of the T-wave is
usually associated with hyperkalaemia it should be
noted that Mg2+ deficient dogs were either normo-
kalaemic (158) or hypokälaemic (157). The flat-
tened or negative T-wave which is usually seen in
hypokälaemic but normomagnesaemic dogs (158)
has also been found in chronic Mg2+ deficient dogs
that had normal serum K+ välues (156).
Interestingly, the profound changes seen in chronic
Mg2+ deficient dogs were not seen in these animals
düring short termed haemodialysis which was de-
signed to produce a selective acute Mg2+ depletion
to approximately one half of its initial plasma^value.
Only a 15% increase of heart rate^nd a slight de^
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crease in the P-R and Q-T intervals were observed
(159). During prolonged dialysis of more than 3—6
hours, the electrocardiographic changes associated
with hypomagnesaemia per se were S—T segment
depression and T-wave Inversion (160). It should be
mentioned that none of the authors found a definite
correlation of the electrocardiographic changes with
the extent of hypomagnesaemia. This is true for
chronic Mg2+ deficiency, äs well äs for acute and se-
lective Mg2+ depletion by dialysis.
Chronic äs well äs acute Mg2* deficient dogs show an
increased sensitivity to cardiac glycosides, äs charac-
terized by a lowered threshold dose for toxic ar-
rhythmia (157,160,161) or by a proloriged duration
of digitalis poisoning (162). By recourse to parenter-
al administration of Mg^"1" in dogs rnade acutely Mg2+
deficient via haemodialysis, the cardiac glycoside-in-
duced arrhythmia could be immediately revef sed in-
to sinus rhythm (160). Also, in normomagnesaemic
dogs, cardiac glycoside-induced ventricülar tachy-
cardia coüld be converted into sinus rhythm by Mg2*
infusion (163, 164).
In coiitrast to rats and dogs the chronic Mg—defi-
cient young cebus monkeys devdoped a bradycar^
diä. The rnain and consistent electrographic change
was an elevated S-T segment and a marked peaking
of the T-wave. No arrhythmias were observed. As in
rats and dogs the Mg2*-deficient monkeys showed a
decreased tolerance to cardiac glycoside administra-
tion. The animals were hypomagnesaemic äs well äs
hypokalaemic (165).
In humans, hypomagnesaemia1) may similarly pro-
duce cardiac arrhythmias. However, arrhythmias
and electrocardiographic abnormalities associated
solely with hypomagnesaemia are rare. The few
cases in the literature we are aware of are listed in
table 5. It should be added that no arrhythmias and
only minor electrographic changes could be ob-
served in normal humans subjected to an experimen-
tal dietary induced Mg2+ depletion, resulting in a hy-
pomagnesaemia with values below 0.5 mmol/1 (173).
All the other cases of hypomagnesaemia reported in
the literature provide no further evidence for a Mg2"1"
specific cardiac effect. In some studies the concomit-
ant values of other electrolytes have not been docu-
mented. In other papers hypomagnesaemia has been
shown to be associated with hypokalaemia and/or
changes of serum Ca2"1". Usually this pattern was ob-
served after myocardial infarction. In a study of 342
patients with myocardial infarction reported by
Dyckner et al. (91), 46% were hypomagnesaemic.
The iiicidence of ventricular ectopic beats, ventricu-
lar tachycardia, ventricular fibrillation, atrial fibrilla-
tion, and supraventricular tachycardia of the hypo-
magnesaemic cases was higher than in normomagne-
saemic patients. It should be noted that in 3% of the
patients hypermagnesaemia was detected, and the
iiicidence of AV blocks and supraventricular brady-
cardia was higher in this group. Concerning distur-
l) Hypomagnesaemia is äs yet not unambiguously defined. On
average, the normal serum Mg2"1" concentration amounts to
0.89 mmol/1. The lower limit (± 2 SD) is 0.7 mmol/l. Some
people with serum Mg2+ concentrations below this limit may
develop a tetanic syndrome, but others will not. Perhaps one
explanation for the nonuniform response is that only free ex-
tracellular Mg2"1" is biologically active. Because this value is dif-
ficult to determine, total serum Mg2+ is usually measured. An-
other factor is that in some subjects the consequence of hypo-
magnesaemia, e.g. increased membrane permeability, may be
compensated by a well developed active membrane transport
system.
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bances of other electrolytes, it has been noted that
10% of the patients were hypokalaemic but no anal-
ysis of arrhythmias for isolated hypomagnesaemia
was presented.
In the same study it has been shown that, in approxi-
mately 9% of 563 patients admitted to the cardiac
unit of the hospital with diagnosis other than my-
ocardial infarction, serum Mg2"1" was lower than 0.7
mmol/1; in this group, there was a higher incidence
of supraventricular tachycardia (91).
Furthermore, an association between hypomagne-
saemia and arrhythmias has been described in pa-
tients during open heart surgery using cardiopulmo-
nary bypass. Some of the patients studied remained
in persistent ventricular fibrillation despite Standard
medical therapy. However, successful defibrillation
w^s finally achieved after intravenous Mg2+ adminis-
tration (174). This initial finding was followed by
several investigations on the importance of Mg2+
Supplementation in*open heart surgery or in cardio-
plegic Solutions (for review see I.e. (175)).
In patients with various forms of arrhythmias due to
digitalis poisoning, a high prevalence of hypomagne-
saemia exists (176—180). However, there was no re-
lationship between hypomagnesaemia and cardiac
glycoside concentration in serum (179,180) nor was
there a relation between the type of arrhythmias and
the serum Mg2+ level (176). In these investigations,
Mg2+ was lowered by only 6-15% (178-180) and
sometimes the decrease was so small that it was not
statistically significant (176, 177, 181).
An association between hypomagnesaemia and ar-
rhythmias has also been found in alcoholics during
alcohol withdrawal (3, 168, 182). However, al-
though it is known that hypomagnesaemia may occur
during alcohol withdrawal (183, 184), oiily a limited
number of cases have so far been reported with hy-
pomagnesaemia at the time of arrhythmia, but one
can anticipate that more will be detected in the fu-
ture. Also before onset of delirium^tremens during
chronic alcoholism a hypomagnesaemia may be al-
ready present in up to 40% of the patients. Approxi-
mately 20% of the alcoholics showed a sinus tachy-
cardia, but there are no reports on the prevalence of
hypomagnesaemia in this group (185).
Other cases reported concern the malabsorption
syndrome. Three patients with a hypomagnesaemia
and hypocalcaemia showed S-T segment depres-
sion, slight Prolongation of QT interval and low
wave voltage (186). Another case with hypomagne-
saemia, hypokalaemia and hypercalcaemia had a
prolonged Q-T segment (184).
During the course of exchange transfusion with cit-
rated blood both a hypomagnesaemia and hypocal-
caemia followed by cardiac arrhythmias and seizures
may occür. At a serum Mg2+ concentration below
0.4 mmol/1 a flattening of T-waves was observed
(187—190). However, under this condition the con^
centrations of free Mg2+ and Ca2+ are, äs yet, not
accurately defined.
The correlätion between hypomagnesaemia and ear-
diac arrhythmia is iiot necessarily specific. However,
the beneficial effect of parenteral Mg2+ on various
forms of arrhythmias either in man (191—193) or in
animals (194) has been known for a long time. Un-
fortimately, these authors did not determine Mg2+ in
serum before and aftef Mg2+ administration. In a
quite recent study, it was reported that the frequency
of ventricular ectöpic beats in hypomagnesaemic pa-
tients could be reduced significäntly by infusion of
Mg2+. Although some of the patients were hypoka-
laemic the average K* serum valüe of the Mg2+
treated group was in the normal ränge (195). Iilter-
estingly, some of the above-mentioned cases with se-
lective hypomagnesaemia were reported tp be fe^
fractory against the usual therapy, unless Mg2+ was
given intravenously (3, 167, 170, 171).
The pathophysiologieal mechanisni goveriiing the efc
fect of hypomagnesaemia on arrhythmias is not
known in detail. In mpst eases of hypomagnesaemia
other serum electrolytes are also changed. But even
when there is really an isolated hypomagnesaemia,
this also leads to a decrease in cellulär K+ of the
heart, while Ca2+ is increased. This effect may be en-
hanced by the increased catecholamine secfetion in
hypomagnesaemia (31). The lowering of inträcellu-
lar K"1" could lead to a less negative membrane po-
tential, so that the cell would be more easily excited
and arrhythmia could more readily occur. An argu-
ment for the primary role of Mg2+ is the observation
that in cases of hypomagnesaemia with ventriculäf
ectöpic beats, the K+ of skeletal muscle was found to
be reduced and that infusion of K+ did not fesült in
any change in muscular K+ content nor in the fre-
quency of ventricular ectöpic beats. A significant in-
crease of muscular K* and a decrease of freqüeiicy
of ventricular ectöpic beats was observed only after
infusion of Mg?* (195).
Conclusion
Mg2+ deficiency with and without hypomagnesaemia
per se may not caüse myocardial infaretion. Howev-
er, it°may facilitate cätecholamine-stimulated loss of
Mg2+, coronary vasospasm and necroses. Lack of
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Mg2"1" and excess of catecholamines act synergistical-
ly in the heart and the coronary arteries. Moreover,
hypomagnesaemia in combination with myocardial
infarction, digitalis poisoning, or alcohol withdrawal
favours occurrence of arrhythmias. In hypomagne-
saemia, secretion of catecholamines is increased, and
catecholamines can perpetuate hypomagnesaemia
by Stimulation of urinary Mg2* loss or increased li-
polysis with trapping of Mg2"1" in the adipocytes äs
Mg2* soaps. To Interrupt the vicious circle that corn-
plicates myocardial infarction and arrhythmias, it
may be reasonable to Supplement with Mg2+ in cases
of hypomagnesaemia. For this purpose, intravenous
administration of Mg24" in saline (196) or, when
used, in a glucose-insulin-K+-solution (93) has ben
recommended.
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